The round was led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital, to expand its enterprise BasilIntel SaaS platform, deepen product capabilities, and accelerate the deployment of data-driven insights across the pharma and medical device industry.

Basil Systems delivers an AI-powered SaaS platform transforming how pharma and MedTech companies manage regulatory, clinical, and product lifecycle strategy. By structuring the world's largest indexed database of regulatory, drug, device, and post-market data, Basil helps life sciences organizations accelerate development, reduce risk, and improve product performance. Trusted by industry leaders, Basil turns complex data into actionable insights that drive better decisions and better patient outcomes.